Quick Answer
Nuo Therapeutics, Inc. reported Total Revenue of $721.0 thousand for fiscal year 2017.
Nuo Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$2.51M -8.1% |
-$2.32M +26.7% |
-$3.17M +0.0% |
-$3.17M -3398.1% |
-$90.7K +0.2% |
-$90.9K +92.4% |
| Diluted EPS | — | — | — | — | -$0.03 -111.1% |
$0.27 +640.0% |
| Total Assets | $1.85M +55.2% |
$1.19M -36.7% |
$1.88M -38.4% |
$3.05M +1837.7% |
$157.3K +1199.1% |
$12.1K -95.6% |
| Cash and Equivalents | $548.9K +93.5% |
$283.7K -69.4% |
$928.7K -54.7% |
$2.05M +1204.3% |
$157.3K +1303.0% |
$11.2K -44.7% |
| Stockholders Equity | -$956.6K -286.2% |
$513.7K -50.6% |
$1.04M -52.6% |
$2.19M +530.3% |
-$509.2K +48.9% |
-$996.2K +17.6% |
| R&D Expense | — | — | — | — | $0.00 | $0.00 -100.0% |
| Operating Income | -$2.52M -2.4% |
-$2.46M +22.4% |
-$3.17M +4.6% |
-$3.32M -3562.3% |
-$90.7K +76.0% |
-$378.1K +61.0% |
| Gross Profit | $2.22M +108.8% |
$1.06M +120.2% |
$482.4K +418.5% |
$93.0K | $0.00 | $0.00 -100.0% |
| Shares Outstanding | 48.18M +2.9% |
46.82M +5.8% |
44.24M +5.8% |
41.80M +38.1% |
30.26M +24.8% |
24.25M +2.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $162.2K | -8.2% | -14.0% |
| Net Income | September 30, 2025 | -$537.9K | +7.0% | +17.2% |
| Diluted EPS | September 30, 2019 | $0.00 | +100.0% | +100.0% |
| Total Assets | September 30, 2025 | $1.93M | +12.1% | +41.8% |
| Cash and Equivalents | September 30, 2025 | $514.8K | -24.7% | +62.7% |
| Stockholders Equity | September 30, 2025 | -$419.6K | -147.1% | +49.1% |
| R&D Expense | September 30, 2019 | $2.7K | -97.2% | -96.8% |
| Operating Income | September 30, 2025 | -$540.1K | +6.4% | +17.2% |
| Gross Profit | September 30, 2025 | $625.4K | +131.2% | +15.6% |
| Shares Outstanding | September 30, 2025 | 47.88M | +2.8% | +2.3% |
- Nuo Therapeutics, Inc. reported Total Revenue of $721.0 thousand for fiscal year 2017.
- Nuo Therapeutics, Inc. showed a decrease of -93.7% in Total Revenue compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported Net Income of -$2.51 million for fiscal year 2025.
- Nuo Therapeutics, Inc. showed a decrease of -8.1% in Net Income compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported Diluted EPS of $0.03 per share (loss) for fiscal year 2021.
- Nuo Therapeutics, Inc. showed a decrease of -111.1% in Diluted EPS compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported Total Assets of $1.85 million for fiscal year 2025.
- Nuo Therapeutics, Inc. showed an increase of +55.2% in Total Assets compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported Cash and Equivalents of $548.9 thousand for fiscal year 2025.
- Nuo Therapeutics, Inc. showed an increase of +93.5% in Cash and Equivalents compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported Stockholders Equity of -$956.6 thousand for fiscal year 2025.
- Nuo Therapeutics, Inc. showed a decrease of -286.2% in Stockholders Equity compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported R&D Expense of $0.00 for fiscal year 2021.
- Nuo Therapeutics, Inc. reported Operating Income of -$2.52 million for fiscal year 2025.
- Nuo Therapeutics, Inc. showed a decrease of -2.4% in Operating Income compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported Gross Profit of $2.22 million for fiscal year 2025.
- Nuo Therapeutics, Inc. showed an increase of +108.8% in Gross Profit compared to the prior fiscal year.
- Nuo Therapeutics, Inc. reported Shares Outstanding of 48.18 million shares for fiscal year 2025.
- Nuo Therapeutics, Inc. showed an increase of +2.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: